Patents by Inventor Andreas Bruederle

Andreas Bruederle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT REGIMENS
    Publication number: 20240209097
    Abstract: The present invention relates to the treatment or prevention of P-selectin mediated disorders, and to anti-P-selectin antibodies or binding fragments thereof, for use in the treatment or prevention of such disorders. In particular, the invention relates to the treatment or prevention of pain crises associated with sickle cell disease, and to anti-P-selectin antibodies or binding fragments thereof, for use in the treatment or prevention of pain crises associated with sickle cell disease.
    Type: Application
    Filed: November 21, 2023
    Publication date: June 27, 2024
    Inventors: Scott ROLLINS, Russell ROTHER, Jonathan STOCKER, Andreas BRUEDERLE
  • USE OF IL-1BETA BINDING ANTIBODIES
    Publication number: 20230088070
    Abstract: Use of an IL-1? binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis, e.g., MDS.
    Type: Application
    Filed: April 25, 2022
    Publication date: March 23, 2023
    Inventors: Andreas BRUEDERLE, Anshu MARATHE, Jean REGARD, Mikael Lee RINNE, Haiying SUN, K. Gary J. VANASSE, Connie WONG
  • USE OF IL-1BETA BINDING ANTIBODIES
    Publication number: 20200369762
    Abstract: Use of an IL-1? binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis, e.g., MDS.
    Type: Application
    Filed: December 18, 2019
    Publication date: November 26, 2020
    Inventors: Andreas BRUEDERLE, Anshu MARATHE, Jean REGARD, Mikael RINNE, Haiying SUN, K. Gary J. VANASSE, Connie WONG
  • TREATMENT REGIMENS
    Publication number: 20200055942
    Abstract: The present invention relates to the treatment or prevention of P-selectin mediated disorders, and to anti-P-selectin antibodies or binding fragments thereof, for use in the treatment or prevention of such disorders. In particular, the invention relates to the treatment or prevention of pain crises associated with sickle cell disease, and to anti-P-selectin antibodies or binding fragments thereof, for use in the treatment or prevention of pain crises associated with sickle cell disease.
    Type: Application
    Filed: November 3, 2017
    Publication date: February 20, 2020
    Inventors: Scott ROLLINS, Russell ROTHER, Jonathan STOCKER, Andreas BRUEDERLE
  • Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
    Patent number: 9642918
    Abstract: The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination of inotuzumab ozogamicin (CMC-544) and temsirolimus. The enhanced antitumor of the combination therapy is particularly useful for patient population that are recalcitrant to inotuzumab ozogamicin or temsirolimus therapy, relapse after treatment with inotuzumab ozogamicin or temsirolimus or where enhanced antitumor effect reduces toxicities associated with treatment using inotuzumab ozogamicin or temsirolimus.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: May 9, 2017
    Assignees: Pfizer Inc., Oncology Institute of Southern Switzerland
    Inventors: Andreas Bruederle, Padraig Moran, Anastasios Stathis
  • COMBINATION OF INOTUZUMAB OZOGAMICIN AND TORISEL FOR THE TREATMENT OF CANCER
    Publication number: 20140335109
    Abstract: The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination of inotuzumab ozogamicin (CMC-544) and temsirolimus. The enhanced antitumor of the combination therapy is particularly useful for patient population that are recalcitrant to inotuzumab ozogamicin or temsirolimus therapy, relapse after treatment with inotuzumab ozogamicin or temsirolimus or where enhanced antitumor effect reduces toxicities associated with treatment using inotuzumab ozogamicin or temsirolimus.
    Type: Application
    Filed: December 4, 2012
    Publication date: November 13, 2014
    Applicant: ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND
    Inventors: Andreas Bruederle, Padraig Moran, Anastasios Stathis